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Invited editorial
The decline of rate and mortality
of acute myocardial infarction.
Almost there, still a long way to go
Federico Lombardi1, Heikki Huikuri2, Georg Schmidt3
and Marek Malik4; on behalf of e-Rhythm Study Group of EHRA
In the last decades, reduction of both hospitalizations
and mortality due to acute myocardial infarction
(AMI) has been reported in many developed countries
and attributed, at least in part, to risk modification at
population level.1–3 Several other mechanisms, such as
prompt and effective coronary revascularization, have
also been shown to be instrumental in the improvement
of patient prognosis. Indeed, a growing number of
patients is now appropriately managed in the acute
and post-acute phase of the index event. Evaluation
of residual myocardial ischaemia as well as appropriate
administration of drugs, including statins, beta-blockers,
ACE inhibitors and dual antiplatelet therapy, represent
the mainstream of therapeutical management for most
of these patients.
In this issue of the journal, Sulo et al.4 has updated
information on trends of incident AMI in Norway
according to data of the ‘Cardiovascular Disease in
Norway 1994–2014’ project. They observed a yearly
decline of AMI diagnoses by 2.6% and 2.8% in
men and women, respectively, that contributed to the
reduction of both AMI hospitalization and mortality.
Declining rates were observed in all age groups. In 18%
of men and 23.3% of women, the first AMI was fatal
and in 20.1% of cases, the death occurred at home,
work place, public places, nursing home or during
transportation. As appropriately recognized by the
authors, the observational design of the study prevents
an appropriate evaluation of the factors responsible for
the observed changes. It is likely that modifications in
the levels of some risk factors, such as smoking or
uncontrolled arterial hypertension, might have played
a positive role.
Whilst there might be regional differences and the
data presented by Sulo et al.4 might not be entirely
representative of other countries, similar trends can
also be observed in other developed countries.3 Hence
it is appropriate to ask whether the contemporary clin-
ical care is on the right track and whether we should
expect further reduction of mortality due to AMI in the
forthcoming years. In our opinion, this is unlikely for
several reasons.
Despite organizational and medical management
advances of the acute phase of AMI that contributed
to a significant decline of in-hospital mortality, death
rates before hospital admission and after hospital dis-
charge have not decreased as we would have wished. As
shown by Sulo et al.,4 the mortality due to ventricular
fibrillation that characterizes the early phase of acute
coronary syndrome and prevents admission and proper
treatment of patients remains high and is only partially
affected by medical and healthcare organization
strategies.5 Drugs such as beta-blockers, angiotensin-
converting enzyme inhibitors and statins may show
their preventive effects on the electrophysiological and
haemodynamic changes associated with an acute cor-
onary event only in patients in whom cardiac diagnosis
has already been made. This leaves the so-called appar-
ently healthy subjects particularly vulnerable. Present
knowledge allows risk modifications in the general
population to be proposed but they require interven-
tions that are difficult to apply without a consistent
support and funding from national healthcare systems.
In this context, the 2016 European Guidelines on car-
diovascular (CV) disease prevention in clinical practice6
recommended ‘systematic CV risk assessment in men
>40 years of age and in women >50 years of age or
post-menopausal with no known CV risk factors may
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be considered’ and that ‘It is recommended to repeat
CV risk assessment every 5 years, and more often for
individuals with risks close to thresholds mandating
treatment’. We already have adequate algorithms for
an automatic analysis of 12-lead electrocardiograms
to detect gross alterations consistent with previous
AMI, left ventricular hypertrophy and bundle branch
block as well as with subtle abnormalities including, for
example, QRS fragmentation and repolarization
changes. All these electrocardiographic deformities
have been associated with an increased mortality
risk.7 A nation-wide screening programme of this size
would be substantial and the cost and management of
such huge amounts of data is a major limiting factor for
its implementation. However, waiting for better times
does not provide any benefit.
The second area of unmet need is the mortality
reduction after hospital discharge. Appropriate and
extensive coronary revascularization, together with
optimal medical therapy have been associated with a
reduction in mortality after the index event. The use
of implantable cardioverter defibrillators on high-risk
patients has also contributed to the observed mortality
reduction. Nevertheless, as indicated in all reports, our
capabilities of identifying patients at high arrhythmic
risk is poor and, in most clinical settings, we only
rely on echocardiographic evaluation of left ventricular
ejection fraction. In the last 30 years, most of
the efforts to develop and validate non-invasive
markers of arrhythmic risk in post-AMI patients have
been frustrated by negative or contrasting results.
Consequently, no indication for non-invasive evalu-
ation of arrhythmic risk excluding imaging techniques
is contained in the recent ESC guidelines for the man-
agement of AMI patients presenting with ST segment
elevation.5 How to explain this when considering
the number of methodologies indicated in Figure 1,
including heart rate variability, heart rate turbulence,
baroreflex sensitivity that have been tested in post-AMI
patients and associated with an increased mortality
risk?8 We have recently addressed this issue9 by con-
sidering two major points. On the one hand, these non-
invasive methodologies have been repeatedly excluded
in large clinical trials and in new population screening
programmes despite the simplicity of obtaining high
quality digital electrocardiographic signals. On the
other hand, most of the new methodologies developed
in the last 10 years utilize analyses of complex systems
that increase the gap between biomedical researchers
and clinical cardiologists. Solving unmet clinical needs
obviously requires more active and more interlinked
inter-disciplinary driven collaboration. [AQ1]
•    QRS fractionation, IVCD
Myocardial conduction
disorders
Repolarization
heterogeneity
Autonomic imbalance
Electrical instability
NON-INVASIVE MARKERS
OF AUTONOMIC
MODULATION AND
ELECTROPHYSIOLOGIC
ALTERATIONS
•    QT variability
•    T wave alternans
•    T wave morphology
•    Tpe interval
•    VPC counts
•    Resting heart rate
•    Heart rate variability
•    Baroreflex sensitivity
•    Heart rate turbulence
•    Deceleration capacity
•    Sympathetic innervation
•    VPC distributions
•    VPC morphology
•    NSVT
•    Signal averaged ECG
•    Bundle branch block
Figure 1. Non-invasive parameters that can be derived from short- or long-term electrocardiographic recordings and have been
used for risk stratification. Adapted from Camm et al.8 and Sassi et al.9
IVCD: intraventricular conduction delay; ECG: electrocardiogram; VPC: ventricular premature contraction; NSVT: non-sustained
ventricular tachycardia [AQ3].
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